Sign Out
Cases of accidental overdose (injection of volumes greater than the recommended 0.05 mL ranibizumab) have been reported from the clinical studies in wet AMD and post-marketing data. Adverse reactions most frequently associated with these reported cases were increased intraocular pressure and eye pain. If an overdose occurs, intraocular pressure should be monitored and treated, if deemed necessary by the attending physician.
In clinical trials doses up to 2 mg of ranibizumab in an injection volume of 0.05 mL to 0.10 mL have been administered to patients with wet AMD and DME. The type and frequency of ocular and systemic adverse events were consistent with those reported for the 0.5 mg (in 0.05 mL) ranibizumab dose.
